Enzyme inhibitors
AssigneeChroma Therapeutics Ltd.
InventorsAlastair David Graham Donald, David Festus Charles Moffat, Andrew James Belfield, Carl Leslie North, Stewart Andrew Wayne Jones
Life of this patent
Estimating the term…
Loading patent…
AssigneeChroma Therapeutics Ltd.
InventorsAlastair David Graham Donald, David Festus Charles Moffat, Andrew James Belfield, Carl Leslie North, Stewart Andrew Wayne Jones
Estimating the term…
Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(C═O)—, —S(═O)2—, —C(C═O)O—, —C(C═O)NR′—, —C(═S)—NR′, —C(═NH)NR′ or —S(═O)2NR— wherein R′ is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)(Alk2)p— wherein in, n, p, Q, AIk1 and AIk2 are as defined in the claims; X1 represents a bond; —C(═O); or —S(═O)2—; —NR4C(═O)—, —C(C═O)NR4—, —NR4C(═O)NR5—, —NR4S(═O)2—, or —S(═O)2NR4— wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; and z is 0 or 1.
A compound of formula (I):
A compound as claimed in any of the preceding claims wherein the radical HONHC(═O)—W— is attached to the ring containing A, B and C in a position meta- or para- to the radical R1R2R3C-NHYL1X1[CH2]z—.
A compound as claimed in any of the preceding claims wherein, in the radical R1R2R3C-NHYL1X1[CH2]—, z is 0.
A compound as claimed in any of the preceding claims wherein, in the radical R1R2R3C-NHYL1X1[CH2]z—, Y is a bond.
A compound as claimed in any of the preceding claims wherein R1 is an ester group of formula R12OC(═O)— wherein R12 is R7R8CR9— wherein
A compound as claimed in any of the preceding claims wherein R1 is an ester group of formula R12OC(═O)— wherein R12 is cyclopentyl.
A compound as claimed in any of the preceding claims wherein one of the substitutents R2 and R3 is a C1-C6 alkyl substituent, and the other is selected from the group consisting of methyl, ethyl, n- and iso-propyl, n-, sec- and tert-butyl, phenyl, benzyl, thienyl, cyclohexyl, and cyclohexylmethyl;
A compound as claimed in any of the preceding claims wherein one of R2 and R3 is methyl or ethyl, and the other is benzyl or C1-C6 alkyl;
A compound as claimed in any of the preceding claims wherein one of R2 and R3 is methyl and the other is methyl, ethyl, n- or iso-propyl, benzyl or n, sec or tert butyl;
A compound as claimed in any of the preceding claims which is in pharmaceutically acceptable salt form.
Dependencies are inferred from the claim text.